Literature DB >> 15122338

Activation of diacylglycerol kinase alpha is required for VEGF-induced angiogenic signaling in vitro.

Gianluca Baldanzi1, Stefania Mitola, Santina Cutrupi, Nicoletta Filigheddu, Wim J van Blitterswijk, Fabiola Sinigaglia, Federico Bussolino, Andrea Graziani.   

Abstract

Vascular endothelial growth factor-A (VEGF-A) promotes angiogenesis by stimulating migration, proliferation and organization of endothelium, through the activation of signaling pathways involving Src tyrosine kinase. As we had previously shown that Src-mediated activation of diacylglycerol kinase-alpha (Dgk-alpha) is required for hepatocytes growth factor-stimulated cell migration, we asked whether Dgk-alpha is involved in the transduction of angiogenic signaling. In PAE-KDR cells, an endothelial-derived cell line expressing VEGFR-2, VEGF-A165, stimulates the enzymatic activity of Dgk-alpha: activation is inhibited by R59949, an isoform-specific Dgk inhibitor, and is dependent on Src tyrosine kinase, with which Dgk-alpha forms a complex. Conversely in HUVEC, VEGF-A165-induced activation of Dgk is only partially sensitive to R59949, suggesting that also other isoforms may be activated, albeit still dependent on Src tyrosine kinase. Specific inhibition of Dgk-alpha, obtained in both cells by R59949 and in PAE-KDR by expression of Dgk-alpha dominant-negative mutant, impairs VEGF-A165-dependent chemotaxis, proliferation and in vitro angiogenesis. In addition, in HUVEC, specific downregulation of Dgk-alpha by siRNA impairs in vitro angiogenesis on matrigel, further suggesting the requirement for Dgk-alpha in angiogenic signaling in HUVEC. Thus, we propose that activation of Dgk-alpha generates a signal essential for both proliferative and migratory response to VEGF-A165, suggesting that it may constitute a novel pharmacological target for angiogenesis control. Copyright 2004 Nature Publishing Group

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15122338     DOI: 10.1038/sj.onc.1207633

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  27 in total

1.  Molecular Pathways: Targeting Diacylglycerol Kinase Alpha in Cancer.

Authors:  Benjamin Purow
Journal:  Clin Cancer Res       Date:  2015-09-29       Impact factor: 12.531

2.  DGKA Provides Platinum Resistance in Ovarian Cancer Through Activation of c-JUN-WEE1 Signaling.

Authors:  Jie Li; Chaoyun Pan; Austin C Boese; JiHoon Kang; Anna D Umano; Kelly R Magliocca; Wenqing Yang; Yu Zhang; Sagar Lonial; Lingtao Jin; Sumin Kang
Journal:  Clin Cancer Res       Date:  2020-04-27       Impact factor: 12.531

3.  Diacylglycerol kinase α deficiency alters inflammation markers in adipose tissue in response to a high-fat diet.

Authors:  Emmani B M Nascimento; Louise Mannerås-Holm; Alexander V Chibalin; Marie Björnholm; Juleen R Zierath
Journal:  J Lipid Res       Date:  2017-12-12       Impact factor: 5.922

4.  Prioritization of driver mutations in pancreatic cancer using cancer-specific high-throughput annotation of somatic mutations (CHASM).

Authors:  Hannah Carter; Josue Samayoa; Ralph H Hruban; Rachel Karchin
Journal:  Cancer Biol Ther       Date:  2010-10-01       Impact factor: 4.742

5.  SAP-mediated inhibition of diacylglycerol kinase α regulates TCR-induced diacylglycerol signaling.

Authors:  Gianluca Baldanzi; Andrea Pighini; Valentina Bettio; Elena Rainero; Sara Traini; Federica Chianale; Paolo E Porporato; Nicoletta Filigheddu; Riccardo Mesturini; Shuping Song; Tamas Schweighoffer; Laura Patrussi; Cosima T Baldari; Xiao-Ping Zhong; Wim J van Blitterswijk; Fabiola Sinigaglia; Kim E Nichols; Ignacio Rubio; Ornella Parolini; Andrea Graziani
Journal:  J Immunol       Date:  2011-11-02       Impact factor: 5.422

6.  A miR-297/hypoxia/DGK-α axis regulating glioblastoma survival.

Authors:  Benjamin Kefas; Desiree H Floyd; Laurey Comeau; Alyse Frisbee; Charli Dominguez; Charles G Dipierro; Fadila Guessous; Roger Abounader; Benjamin Purow
Journal:  Neuro Oncol       Date:  2013-10-24       Impact factor: 12.300

7.  Targeting the mesenchymal subtype in glioblastoma and other cancers via inhibition of diacylglycerol kinase alpha.

Authors:  Inan Olmez; Shawn Love; Aizhen Xiao; Laryssa Manigat; Peyton Randolph; Brian D McKenna; Brian P Neal; Salome Boroda; Ming Li; Breanna Brenneman; Roger Abounader; Desiree Floyd; Jeongwu Lee; Ichiro Nakano; Jakub Godlewski; Agnieszka Bronisz; Erik P Sulman; Marty Mayo; Daniel Gioeli; Michael Weber; Thurl E Harris; Benjamin Purow
Journal:  Neuro Oncol       Date:  2018-01-22       Impact factor: 12.300

8.  Diacylglycerol kinase-alpha mediates hepatocyte growth factor-induced epithelial cell scatter by regulating Rac activation and membrane ruffling.

Authors:  Federica Chianale; Santina Cutrupi; Elena Rainero; Gianluca Baldanzi; Paolo E Porporato; Sara Traini; Nicoletta Filigheddu; Viola F Gnocchi; Massimo M Santoro; Ornella Parolini; Wim J van Blitterswijk; Fabiola Sinigaglia; Andrea Graziani
Journal:  Mol Biol Cell       Date:  2007-09-26       Impact factor: 4.138

9.  Diacylglycerol kinase delta and protein kinase C(alpha) modulate epidermal growth factor receptor abundance and degradation through ubiquitin-specific protease 8.

Authors:  Jinjin Cai; Tracy M Crotty; Ethan Reichert; Kermit L Carraway; Diana M Stafforini; Matthew K Topham
Journal:  J Biol Chem       Date:  2010-01-11       Impact factor: 5.157

10.  Diacylglycerol kinase α is a critical signaling node and novel therapeutic target in glioblastoma and other cancers.

Authors:  Charli L Dominguez; Desiree H Floyd; Aizhen Xiao; Garrett R Mullins; Benjamin A Kefas; Wenjun Xin; Melissa N Yacur; Roger Abounader; Jae K Lee; Gabriela Mustata Wilson; Thurl E Harris; Benjamin W Purow
Journal:  Cancer Discov       Date:  2013-04-04       Impact factor: 39.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.